📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice. (2019)

First Author: Klein AF

Attributed to: Advanced peptide-oligonucleotide therapy for Myotonic Dystrophy Type 1 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1172/jci128205

PubMed Identifier: 31479430

Publication URI: http://europepmc.org/abstract/MED/31479430

Type: Journal Article/Review

Volume: 129

Parent Publication: The Journal of clinical investigation

Issue: 11

ISSN: 0021-9738